TMB as New Biomarker in NSCLC — Ready for Clinic?

A new biomarker — high tumor mutational burden (TMB) — identifies lung cancer patients who do better on immunotherapy than on chemotherapy.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply